Related Experiment Video
Updated: Jul 2, 2026

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin (sh)RNA
Published on: February 12, 2020
[Effect of shRNA targeted to beta-catenin on K562 cell growth]
Zeng-Jun Li1, Qian Li, Guo-Rong Wang
1Chinese Academy of Medical Science, Peking Union Medical College, Tianjin 300020, China.
Abstract:
In order to investigate the effect of shRNA targeted to beta-catenin on the growth of K562 cells, plasmid containing beta-catenin specific shRNA sequence was transfected into K562 cells by lipofectamine 2000, and G418 was added to screen the positive cells. Real-time PCR and Western blot were used to detect the expression of beta-catenin. Cell growth curve, MTT and colony forming cell assays were used to evaluate the proliferation potential of cells. The results showed that the mRNA level of beta-catenin was reduced significantly in K562 cells transfected into interfering plasmid as compared with control plasmid, while the protein level failed to demonstrate difference by the time of 72 hours after transfection. After long-term culture with G418, the count of positive cells enhanced in control group while no positive cells survived in the interfering group. Colony-forming cell assays revealed that the K562 cells in interfering group formed colonies with very small size and low forming rate, compared with the control group, though the growth curve and MTT failed to illustrate differences. It is concluded that the beta-catenin-specific shRNA mediated by plasmid can effectively knockdown the expression of beta-catenin gene and inhibit the colony-forming ability in K562 cells, it is a potential target for the therapy of CML, even in blast crisis.
Insights
Short hairpin RNA (shRNA) targeting beta-catenin effectively inhibited K562 cell growth and colony formation. This suggests beta-catenin is a potential therapeutic target for chronic myeloid leukemia (CML).
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Context:
- K562 cells are a human chronic myeloid leukemia (CML) cell line.
- Beta-catenin is a key protein in the Wnt signaling pathway, often implicated in cancer cell proliferation and survival.
- Investigating the role of beta-catenin in CML is crucial for developing targeted therapies.
Purpose:
- To investigate the effect of beta-catenin specific shRNA on K562 cell proliferation.
- To assess the efficacy of shRNA-mediated gene knockdown on beta-catenin expression.
- To evaluate the therapeutic potential of targeting beta-catenin in CML.
Summary:
- shRNA targeting beta-catenin was transfected into K562 cells.
- Real-time PCR confirmed significant reduction in beta-catenin mRNA, though protein levels showed no difference at 72 hours.
- Colony-forming assays demonstrated inhibited colony formation and size in shRNA-treated cells, suggesting impaired proliferation.
- While growth curves and MTT assays showed no significant differences, long-term culture revealed no survival of positive cells in the interfering group.
Impact:
- Beta-catenin-specific shRNA effectively suppresses K562 cell colony-forming ability.
- This study highlights beta-catenin as a potential therapeutic target for chronic myeloid leukemia, including blast crisis.
- Further research into beta-catenin inhibition could lead to novel CML treatment strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity